Major Cardiovascular Events Linked to Metabolic Acidosis
Cardiovascular events are the leading cause of death among patients with chronic kidney disease, and metabolic acidosis in this population is underdiagnosed.
Metabolic Disorders
Sodium Bicarbonate May Mitigate Calcium Phosphate Stone Risk in CKD
Oral sodium bicarbonate therapy given to patients with chronic kidney disease increases urinary pH but also increases urinary citrate levels, which may mitigate the risk for calcium phosphate stone formation.
Low Bicarbonate in Kidney Transplant Recipients Predicts Graft Failure
Each 1 mEq/L increase in serum bicarbonate in kidney transplant recipients is associated with a 10% reduction in graft failure risk, a study found.
Lower Bicarbonate in ADPKD Linked to Worsening Kidney Outcomes
A study of patients with ADPKD found that each 1 mmol/L decrease in serum bicarbonate was significantly associated with a 21% increased risk for worsening kidney function.
Metabolic Acidosis Ups Risk of CKD Progression to Renal Replacement Therapy
Metabolic acidosis in patients with chronic kidney disease increases their likelihood of requiring dialysis or a kidney transplant, a study found.
Fruits, Vegetables May Offer Edge in Correcting Metabolic Acidosis in CKD
Increased intake of fruits and vegetables corrects CKD-related metabolic acidosis as well as sodium bicarbonate supplements, but is associated with other health benefits, a new post hoc analysis found.
Venous pH May Inform Treatment of CKD-Related Metabolic Acidosis
In patients with acidemia, hypobicarbonatemia conferred a considerable risk of kidney failure requiring renal replacement therapy after adjusting for potential confounders.
FDA Cites Deficiencies in Veverimer NDA for Metabolic Acidosis in CKD
Veverimer is a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD.
Procysbi Delayed-Release Oral Granules Now Available in Packets
Horizon Therapeutics announced the availability of Procysbi (cysteamine bitartrate) delayed-release oral granules in tear-open packets for the treatment of nephropathic cystinosis in patients aged 1 year and older.
FDA Approves Procysbi Delayed-Release Oral Granules in Packets
The FDA has approved Procysbi (cysteamine bitartrate; Horizon Therapeutics) delayed-release oral granules, a new formulation for the treatment of nephropathic cystinosis in patients aged 1 year and older.
- Loading...
Loading...
Next post in Nephrology
Loading... 
Loading...